



Cetuximab mAb-based ELISA Assay Kit

Catalog Number:

IG-AB112 (1 x 96 wells)

For Research Use Only. Not for use in diagnostic procedures.

v. 1.0

Eagle Biosciences, Inc.
20A Northwest Blvd., Suite 112, Nashua, NH 03063
Phone: 617-419-2019 Fax: 617-419-1110
www.EagleBio.com

**Introduction**

The drug Cetuximab (trade name Erbitux®) is a human-mouse chimeric immunoglobulin (IgG1 · monoclonal antibody (mAb), selectively directed against the epidermal growth factor receptor (EGFR), also known as HER1 or ErbB1. Since its approval by Food and Drug Administration for cancer treatment in 2004, Cetuximab became widely used in the treatment of colorectal and head and neck cancers.

The *ImmunoGuide* Cetuximab ELISA (mAb-based) kit can be efficiently used for measuring free Cetuximab levels in serum and plasma.

Intended Use

Enzyme immunoassay for the specific and quantitative determination of free Cetuximab in serum and plasma.

Assay Principle

This ELISA is based on Cetuximab-specific mouse monoclonal antibody (catcher Ab, *ImmunoGuide* clone IG-FB7D9). Diluted standards and samples are incubated in the microtiter plate coated with IG-FB7D9 mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Cetuximab. Following incubation, wells are washed, and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Cetuximab in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Cetuximab to the solid phase, pre-coated with IG-FB7D9, is inhibited by recombinant human epidermal growth factor receptor (rh-EGFR) protein in a concentration dependent manner. Therefore, the *ImmunoGuide* Cetuximab ELISA (mAb-Based) measures the free form of Cetuximab.



Warnings and Precautions

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact *Eagle Biosciences* or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
6. Chemicals and prepared or used reagents have to be treated as hazardous waste according to the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it has been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

Storage and Stability

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

**Kit Components/Materials Provided**

Quantity	Component
1 x 12 x 8	Microtiter ELISA Plate Break apart strips coated with anti-Cetuximab monoclonal antibody.
5 x 0.5 mL	Cetuximab Standards A-E, Concentrate (10X) 2000; 600; 200; 60; and 0 ng/mL Used for construction of the standard curve. Contains Cetuximab, proteins, preservative and stabilizer.
1 x 12 mL	Assay Buffer Blue colored. Ready to use. Contains proteins and preservative.
1 x 60 mL	Dilution Buffer, Concentrate (5X) Contains orange dye, proteins and preservative.
1 x 12 mL	Enzyme Conjugate Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin [®] and stabilizers.
1 x 12 mL	TMB Substrate Solution Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
1 x 12 mL	Stop Solution Ready to use. 1 N Hydrochloric acid (HCl).
1 x 50 mL	Wash Buffer, Concentrate (20x) Contains buffer, Tween [®] 20 and Kathon [™] .
2 x 1	Adhesive Seal For sealing microtiter plate during incubation.

Required Materials that are not supplied

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.



Handling/Storage

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage: 2-8°C, Stability: 3d

Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles

Procedural Notes

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

Preparation of Components

Dilute/ dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer	up to 200 mL	Distilled Water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	4 w
10 mL	Dilution Buffer	up to 50 mL	Distilled Water	1:5		2-8 °C	4 w



Dilutions of Standards and Samples

The dilutions depicted below are examples of how to obtain final dilutions for standards and samples. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 10 μ L of standard or sample added to 90 μ L of 1X dilution buffer, giving the total volume of 100 μ L and a dilution of 1:10.
2. 10 μ L of 1:10 diluted sample added to 990 μ L of 1X dilution buffer, giving the total volume of 1000 μ L and a final dilution of 1:1000. This 2nd dilution step should not be done for the standards.
3. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

Test Procedure

- Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
- All Standards should be run with each series of unknown samples.
- Standards should be subject to the same manipulations and incubation times as the samples being tested.
- All steps of the test should be completed without interruption.
- Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.
- The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.



Assay Procedure

1.	Pipette 100 μ l of Assay Buffer into each of the wells to be used.
2.	<p>Pipette 75 μL of each 1:10 the Diluted Standard, and 1:1000 Diluted Samples into microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided.</p> <p>A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Samples (Serum/Plasma)</p>
3.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 60 min at room temperature (RT, 2025°C).
4.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 μ L of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
5.	Pipette 100 μ L of Enzyme Conjugate (HRP-anti human IgG mAb) into each well.
6.	Cover plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 30 min at RT.
7.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 μ L of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
8.	Pipette 100 μ L of Ready-to-Use TMB Substrate Solution into each well.
9.	Incubate 10 min at RT. Avoid exposure to direct sunlight.
10.	Stop the substrate reaction by adding 100 μ L of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
11.	Measure optical density (OD) with a photometer at 450 nm (Reference at OD620 nm is optional) within 15 min after pipetting the Stop Solution.



Quality Control

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

Calculations of Results

A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>. The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor (usually 1000). If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also, this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.


Typical Calibration Curve

(All steps were performed at 23°C. Just an example. Do not use it for calculation!)

1:10 Diluted Standard	A	B	C	D	E
Concentration (ng/mL)	200	60	20	6	0
Mean OD450/620 nm	2.990	1.270	0.520	0.170	0.015



Typical Graph



Assay Characteristics

Specificity:

There is no cross reaction with any other proteins present in native human serum. A screening test was performed with 48 different native human sera. All produced OD_{450/620 nm} values (ranged from 0.011 to 0.058) less than the mean OD (0.125) of standard D (6 ng/mL). In addition, binding of Cetuximab is inhibited by recombinant human epidermal growth factor receptor (hEGFR) protein in a concentration dependent manner. Therefore, the ImmunoGuide Cetuximab ELISA (mAb-Based) measures the biologically active free form of Cetuximab, i.e. not pre-occupied by human EGF Receptor. No cross reaction was observed with sera spiked with the other therapeutic antibodies including Infliximab, Adalimumab, Etanercept, Rituximab, Tocilizumab, Trastuzumab, Aflibercept and Bevacizumab at concentrations up to 2 mg/mL. All produced mean OD_{450/620 nm} values ranged from 0.009 to 0.027.

Sensitivity:

The lowest detectable level that can be clearly distinguished from the zero standard is 2 ng/mL (zero standard +2SD read from the curve) under the abovedescribed conditions. Analytical sensitivity is 2 ng/mL, and corresponding to the detection limit (limit of quantification) of 2 µg/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:1000 before starting the assay.

Precision:

Intra-assay CV: <10%.
Inter-assay CV: <10%.

Recovery:

Recovery rate was found to be >95% with native human serum and plasma samples when spiked with exogenous Cetuximab.



Automation

The *ImmunoGuide* Cetuximab ELISA (mAb-based) is suitable also for being used by an automated ELISA processor.

References

1. Greening DW, Lee ST, Ji H, Simpson RJ, Rigopoulos A, Murone C, Fang C, Gong S, O'Keefe G, Scott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. *Oncotarget*. 2015;6(35):38166-80.
2. Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, Negrini M. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. *BMC Cancer*. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5.
3. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. *Ann Oncol*. 2010;21(7):1537-45.
4. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. *Cancer*. 2007;110(3):581-9.
5. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. *Clin Cancer Res*. 2006;12(21):6517-22.
6. Lu X, Chen X, Sun J, Gao P, Song Y, Huang X, Luo Y, Chen P, Wang Z. Polymorphism in epidermal growth factor is related to clinical outcomes of metastatic colorectal cancer patients treated with cetuximab: a systematic review and meta-analysis. *Int J Clin Exp Med*. 2015;8(7):10929-37.
7. Boeckx C, Blockx L, de Beeck KO, Limame R, Camp GV, Peeters M, Vermorken JB, Specenier P, Wouters A, Baay M, Lardon F. Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. *Am J Cancer Res*. 2015;5(6):1921-38.
8. Kurokawa M, Watanabe Nemoto M, Harada R, Kobayashi H, Horikoshi T, Kanazawa A, Togasaki G, Abe Y, Chazono H, Hanazawa T, Okamoto Y, Uno T. Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients. *J Radiat Res*. 2015;56(5):849-55.
9. de Boer E, Warram JM, Tucker MD, Hartman YE, Moore LS, de Jong JS, Chung TK, Korb ML, Zinn KR, van Dam GM, Rosenthal EL, Brandwein-Gensler MS. In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. *Sci Rep*. 2015 Jun 29;5:10169. doi: 10.1038/srep10169
10. Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Mugnoz FG, Cantore M, Ricci S, Catalano V, Mambrini A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. *World J Gastrointest Oncol*. 2015;7(6):47-54.
11. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. *Cancer Treat Rev*. 2015;41(8):653-9.
12. Li XX, Liang L, Huang LY, Cai SJ. Standard chemotherapy with cetuximab for treatment of colorectal cancer. *World J Gastroenterol*. 2015;21(22):7022-35.



13. Shih YH, Peng CL, Lee SY, Chiang PF, Yao CJ, Lin WJ, Luo TY, Shieh MJ. 111In cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. *Oncotarget*. 2015;6(18):16601-10.
14. Song QB, Wang Q, Hu WG. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. *World J Gastroenterol*. 2015;21(14):4365-72.
15. Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. *Oncol Rep*. 2015;33(5):2135-42.
16. Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. *Cancer Sci*. 2015;106(5):604-10.
17. Stintzing S. Management of colorectal cancer. *F1000Prime Rep*. 2014 Nov 4;6:108. doi: 10.12703/P6-108. eCollection 2014. Review.
18. Shirao K, Yoshino T, Boku N, Kato K, Hamaguchi T, Yasui H, Yamamoto N, Tanigawara Y, Nolting A, Yoshino S. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. *Cancer Chemother Pharmacol*. 2009;64(3):557-64.
19. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. *J Clin Oncol*. 2012;30(32):4017-25.
20. Céze N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, Watier H, Lecomte T, Painsaud G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. *Ther Drug Monit*. 2009;31(5):597-601.



Warranty Information

Eagle Biosciences, Inc. warrants its Product(s) to operate or perform substantially in conformance with its specifications, as set forth in the accompanying package insert. This warranty is expressly limited to the refund of the price of any defective Product or the replacement of any defective Product with new Product. This warranty applies only when the Buyer gives written notice to the Eagle Biosciences within the expiration period of the Product(s) by the Buyer. In addition, Eagle Biosciences has no obligation to replace Product(s) as result of a) Buyer negligence, fault, or misuse, b) improper use, c) improper storage and handling, d) intentional damage, or e) event of force majeure, acts of God, or accident.

Eagle Biosciences makes no warranties, either expressed or implied, except as provided herein, including without limitation thereof, warranties as to marketability, merchantability, fitness for a particular purpose or use, or non-infringement of any intellectual property rights. In no event shall the company be liable for any indirect, incidental, or consequential damages of any nature, or losses or expenses resulting from any defective product or the use of any product. Product(s) may not be resold, modified, or altered for resale without prior written approval from Eagle Biosciences, Inc.

For further information about this kit, its application or the procedures in this kit, please contact the Technical Service Team at Eagle Biosciences, Inc. at info@eaglebio.com or at 866-411-8023.